Amundi announces the appointment of Eric Wohleber as Head of Real & Alternative Assets Sales.
Eric Wohleber, Head of Real & Alternative Assets Sales
Eric started his career in 1994 in the marketing department of UAP Insurance (AXA Group), and joined INVESCO France in 1995, where he worked for more than ten years, on different Sales and Marketing positions, mainly on the Retail side. In 2006, he moved to Barclays Global Investors (BGI) in London to prepare the launch of the French Branch and to lead the iShares ETF Sales in France. In 2007, after the launch of the Branch in Paris, he was nominated Country Manager for BGI France and built a local Sales team. In 2009, when BlackRock acquired BGI, he worked on the merger of the two branches and was nominated Country Manager for BlackRock. Since this date, Eric continued to lead the iShares Sales activity and was a permanent member of the EMEA Retail ExCo.
Eric Wohleber holds a PhD in “Banking and financing” from Paris II Assas University.
Amundi, the leading European asset manager, ranking among the top 10 global players, offers its 100 million clients - retail, institutional and corporate - a complete range of savings and investment solutions in active and passive management, in traditional or real assets.
With its six international investment hubs, financial and extra-financial research capabilities and long-standing commitment to responsible investment, Amundi is a key player in the asset management landscape.
Amundi clients benefit from the expertise and advice of 5,300 employees in more than 35 countries. A subsidiary of the Crédit Agricole group and listed on the stock exchange, Amundi currently manages more than €2.0 trillion of assets.
Amundi, a trusted partner, working every day in the interest of its clients and society
- Source: IPE “Top 500 Asset Managers” published in June 2021, based on assets under management as at 31/12/2020
- Boston, Dublin, London, Milan, Paris and Tokyo
- Consolidated internal Amundi and Lyxor workforce as at 01/01/2022
- Amundi data including Lyxor as at 31/12/2021